Twenty-four vs. fourty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in Interferon alpha monotherapy relapsers with chronic hepatitis c

Twenty-four vs. fourty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in Interferon alpha monotherapy relapsers with chronic hepatitis c

Bibliographic Details
Main Authors:	BSE August-Jörg, R Hermann, M Weitz, E Renner
Format:	Article
Language:	English
Published:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2003-08-01
Series:	Swiss Medical Weekly
Subjects:	SASL Ribavirin Interferonalpha combination therapy Relapse Hepatitis C
Online Access:	https://www.smw.ch/index.php/smw/article/view/299

Similar Items

Hepatitis C: an update
by: Swiss Medical Weekly
Published: (2001-06-01)

Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C
by: Yasser K. Rashed, et al.
Published: (2020-02-01)

Therapy with interferon-alpha plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus
by: Edmundo P.A. Lopes, et al.

A Comparison of Interferon-Alpha-2b Induction Therapy with Interferon-Alpha-2b Plus Ribavirin Combination Therapy for the Treatment of Chronic Hepatitis C
by: Bilgehan AYGEN, et al.
Published: (2004-09-01)

Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy
by: Luis Jesuino de Oliveira Andrade, et al.

Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin: a review
by: Luis Jesuíno de Oliveira Andrade, et al.

Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4
by: Juan José Urquijo, et al.
Published: (2013-01-01)

Effect of Pegylated Interferon on Non-Responders and Relapsers with Interferon
by: Hisham O. Akbar, et al.
Published: (2002-04-01)

Lymph node enlargement during combination therapy for chronic hepatitis C with pegylated interferon alpha and ribavirin: harmless reaction or harmful disease?
by: M Wilhelmi, et al.
Published: (2006-01-01)

Interferon alpha-2b and ribavirin as combined therapy for chronic hepatitis C in Cuba: National Program
by: Hugo Nodarse-Cuní, et al.

No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
by: Yin-Qiu Huang, et al.
Published: (2020-07-01)

Efficacy of triple therapy with interferon alpha-2b, ribavirin and amantadine in the treatment of naïve patients with chronic hepatitis C
by: Hamid Kalantari, et al.
Published: (2007-08-01)

Autoimmune thyroid diseases in patients with chronic hepatitis C treated by pegylated interferon-alpha and ribavirin: A prospective study
by: Ružić Maja, et al.
Published: (2017-01-01)

Interferon-ribavirin therapy for chronic hepatitis C: Efficacy in Saudi patients
by: Sandokji Abdulkareem, et al.
Published: (2003-01-01)

The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients
by: Nishikawa Hiroki, et al.
Published: (2012-03-01)

Suppression of ribosomal protein synthesis and protein translation factors by Peg-interferon alpha/ribavirin in HCV patients blood mononuclear cells (PBMC)
by: Gupta Rahul, et al.
Published: (2012-03-01)

Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]
by: Delwaide Jean, et al.
Published: (2003-08-01)

Therapy with interferon-a plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus
by: Lopes Edmundo P.A., et al.
Published: (2003-01-01)

Retinal Changes In Patients with Hepatitis C Virus under treatment with interferon and ribavirin.
by: Mansour Hassan, et al.
Published: (2020-01-01)

Molde brônquico devido ao uso de interferon peguilado e ribavirina Bronchial casts attributed to the use of pegylated interferon and ribavirin
by: Eduardo Garcia, et al.
Published: (2009-07-01)

ORIGINAL PAPER <br>Combined interferon-alpha-2b and ribavirin therapy in patients with recurring chronic hepatitis C (genotype 1) following liver transplantation in Hungary
by: Gabriella Lengyel, et al.
Published: (2005-04-01)

Antiviral/immunomodulatory combination therapy: Pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection
by: Delić Dragan, et al.
Published: (2012-01-01)

Hematological Side Effects During Combination Therapy With Interferon and Ribavirin In Chronic Hepatitis C
by: Komal Owais
Published: (2015-06-01)

PREDICTORS OF SUSTAINED VIROLOGICAL RESPONSE (SVR) TO PEGYLATED INTERFERON ALPHA (PEG-IFN α) AND RIBAVIRIN (RBV) IN PATIENTS WITH CHRONIC HEPATITIS C INFECTED WITH GENOTYPE 1.
by: Krasimir Antonov, et al.
Published: (2011-12-01)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
by: Janine Hartl, et al.
Published: (2012-07-01)

Extended treatment with interferon and ribavirin in a hemodialysis patient with chronic hepatitis C
by: Aline Gonzalez Vigani, et al.

Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis
by: Edison Roberto Parise, et al.

PEG-INTERFERON ALPHA-2A AND LOW-DOSE RIBAVIRIN FOR TREATMENT OF HEPATITIS C VIRUS INFECTION IN PATIENTS WITH SICKLE CELL ANEMIA IN SAUDI ARABIA.
by: Adnan Agha
Published: (2014-08-01)

Pegylated Interferon (Alone or With Ribavirin) for Chronic Hepatitis C in Haemodialysis Population
by: Mario Espinosa, et al.
Published: (2015-05-01)

Ocular manifestations in Egyptian children with chronic hepatitis C treated with pegylated interferon and ribavirin
by: Dalia H.A.R Khalil, et al.
Published: (2016-01-01)

Treatment of human papillomavirus with peg-interferon alfa-2b and ribavirin
by: M.H.P. Pavan, et al.

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C
by: Byung Chul You, et al.
Published: (2012-09-01)

Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy
by: E. Parise, et al.

Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C
by: Patruno Savino FA, et al.
Published: (2002-08-01)

Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting
by: Sergio Sabbatani, et al.

Evaluation of combination therapy with Interferon and Ribavirin in patients with chronic hepatitis C : a genotype based study
by: Y. Bafandeh, et al.
Published: (2007-01-01)

Addition of pentoxifylline to pegylated interferon-alpha-2a and ribavirin improves sustained virological response to chronic hepatitis C virus: a randomized clinical trial
by: Miguel Ángel Jiménez-Luévano, et al.
Published: (2013-03-01)

Adverse Skin Reactions due to Ribavirin in Hepatitis C Combination Therapy with Pegylated Interferon-α2a
by: Masahisa Shindo, et al.
Published: (2013-12-01)

Histological response study of chronic viral hepatitis C patients treated with interferon alone or combined with ribavirin
by: Kleber Prado, et al.

Efficacy of ribavirin and interferon-α therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study
by: Hui Li, et al.
Published: (2021-03-01)